No Data
BofA Securities Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $63
Clear Street Initiates Akero Therapeutics(AKRO.US) With Buy Rating, Announces Target Price $49
Express News | Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the Easl Congress 2025
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
Akero Therapeutics Initiated With a Buy at Clear Street
$AKRO Stock Is up 2% Today. Here's What We See in Our Data.